Celltrion launches Remicade biosimilar in Europe

Celltrion Inc. (KOSDAQ:068270) launched Remsima infliximab ( CT-P13) in 12 European countries including Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the U.K. Remsima is a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK).

Celltrion's co-exclusive partner Hospira Inc. (NYSE:HSP) markets the biosimilar independently as Inflectra in 24 European countries, including many where Celltrion is launching Remsima (see BioCentury Extra, Feb. 17, 2015). ...